Paper Details

  1. Home
  2. Paper Details

Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.

Author: Abu-ArjaRolla, AbusinGhada, CabralLinda, DingHilda, HashemHasan, LazarusHillard M, RangarajanHemalatha

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report describes a 13-year-old boy with Fanconi anemia (FA) and refractory acute myeloid leukemia (AML) who achieved morphologic remission after treatment with azacitidine, an epigenetic modifying agent. The patient underwent a hematopoietic cell transplant (HCT) but relapsed 95 days later. Azacitidine was used again as salvage therapy, along with donor lymphocyte infusion (DLI), and was well tolerated. This case suggests that azacitidine may be a viable alternative to conventional chemotherapy in patients with FA and AML.
Paper Details　
Original Abstract of the Article :
HCT is the definitive therapy for patients with FA and AML. Conventional cytotoxic agents cause potential DNA damage, and currently, there is no established regimen for these patients prior to HCT. A 13-year-old male with FA and refractory AML was given azacitidine, achieved morphologic remission an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/petr.12870

データ提供：米国国立医学図書館（NLM）

Fanconi Anemia and Acute Myeloid Leukemia: A Challenging Journey

Fanconi anemia and acute myeloid leukemia (AML) are challenging conditions, like traversing a treacherous desert landscape. This research presents a case report of a pediatric patient with Fanconi anemia and refractory AML who was treated with azacitidine as a bridge to allogeneic hematopoietic cell transplantation (HCT). The study explores the potential of azacitidine as an alternative to conventional chemotherapy in this complex patient population.

Azacitidine: A Promising Oasis in a Challenging Terrain

The case report suggests that azacitidine may be a viable option for patients with Fanconi anemia and AML, offering a potentially less toxic approach to achieving remission before HCT. This is like finding a hidden oasis in the desert, providing a respite from the harsh conditions and offering a path toward a brighter future.

Hope for Patients: A New Path Forward

This research provides hope for patients with Fanconi anemia and AML, offering a potential alternative to conventional chemotherapy that could lead to better outcomes and reduced toxicity. This is a significant development in the ongoing quest to find effective treatments for this complex and challenging disease.

Dr.Camel's Conclusion

This case report offers a glimmer of hope in the challenging landscape of Fanconi anemia and AML. Azacitidine, as a bridge to HCT, shows promise for improving outcomes and reducing treatment-related toxicity. This research is a reminder that even in the most challenging terrains, there is always potential for finding new solutions and paving a path toward a brighter future.
Date :
  1. Date Completed 2017-05-18
  2. Date Revised 2017-05-18
Further Info :

Pubmed ID

27976488

DOI: Digital Object Identifier

10.1111/petr.12870

Related Literature

Article Analysis
・Side Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.